Drugs / CS3002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04162301 | Dec 2019 → Feb 2021 | neoplasm | CStone Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS3002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162301 ↗ |
| Action | Inhibit | “CS3002, a CDK4/6 Inhibitor” NCT04162301 ↗ |
| Modality | Small molecule | “CS3002, a CDK4/6 Inhibitor” NCT04162301 ↗ |
| Route | Oral | “orally administered” NCT04162301 ↗ |